Recombinant Human IL3RA Protein (Met1-Arg305), HlgG1 Fc-tagged

• Cat.No.: IL3RA-1120H
• Product Overview: Recombinant Human IL3RA Protein (NP_002174.1) (Met1-Arg305) was produced by HEK293 Cells expression system. This protein was expressed with the Fc region of human IgG1 at the C-terminus.

Specification

• Description: Interleukin-3 receptor subunit alpha, also known as IL-3 receptor subunit alpha, IL-3R-alpha, CD123, and IL3RA, is a single-pass type I membrane protein which belongs to the type I cytokine receptor family and Type 5 subfamily. The specific alpha subunit of the interleukin-3 receptor (IL-3Ralpha, CD123) is strongly expressed in various leukemic blasts and leukemic stem cells and seems to be an excellent target for the therapy of leukemias. The WSXWS motif of IL3RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box one motif of IL3RA is required for JAK interaction and / or activation. IL3RA represents a unique marker for primitive leukemic stem cells. Targeting of IL3RA may be a promising strategy for the preferential ablation of AML cells. Aberrant IL3RA expression is a good marker for monitoring of minimal residual disease. IL3RA is strongly expressed in various leukemic blasts and leukemic stem cells and seems to be an excellent target for the therapy of leukemias. Recent studies have shown that interleukin-3 receptor alpha (CD123) is highly expressed on leukemia stem cells of patients with acute myeloid leukemia, and is correlated with tumor load and poor prognosis. CD123 was highly expressed in the bone marrow of the patients with myelodysplastic syndrome (MDS), significantly correlated with the proportion of bone marrow blasts, and thus might be the marker of MDS malignant clone. IL3RA is also a useful new marker for distinguishing B-cell disorders with circulating villous lymphocytes as its expression is characteristic of typical hairy cell leukemia (HCL) with high sensitivity and specificity.
• Source: HEK293
• Species: Human
• Tag: Fc
• Predicted N Terminal: Thr 19
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human IL3RA consists of 525 amino acids and predicts a molecular mass of 59.8 kDa.
• Protein length: Met1-Arg305
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE.
• Stability: Samples are stable for up to twelve months from date of receipt at -70 centigrade.
• Storage: Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Shipping: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
  Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Gene Information

• Gene Name: IL3RA interleukin 3 receptor, alpha (low affinity) [ Homo sapiens ]
• Official Symbol: IL3RA
• Synonyms: IL3RA; CD123; IL-3RA; IL-3R-alpha; CD123 antigen; IL3R; IL3RX; IL3RY; IL3RAY; hIL-3Ra; MGC34174
• Gene ID: 3563
• mRNA Refseq: NM_002183
• Protein Refseq: NP_002174
• MIM: 308385
• UniProt ID: P26951

Reviews

07/24/2022

In special environment, good stability.

05/25/2022

Good crystallization property and good effect.

06/29/2021

Has the expected biological activity, such as enzyme activity and receptor binding activity, and so on.

Q&As

Can Il3ra be personalized?

The feasibility of personalized therapy depends on the specific disease type and patient situation, and more research is needed to determine the application of personalized therapy to Il3ra.

Does Il3ra have clinical application prospects? What are the prospects?

Il3ra has certain promise in clinical application, especially in the treatment of immune-related diseases.

What is the action mechanism of Il3ra?

Regulates the proliferation and differentiation of immune cells by binding to its interacting cytokine IL-3, and plays a role in regulating the function of the immune system.

How is the clinical trial of Il3ra progressing?

Clinical trials of recombinant Il3ra have been conducted in different disease areas. At present, some early trials show its potential in the treatment of certain diseases, but more research is needed to verify its efficacy and safety.

What is the specific effect of Il3ra on the immune system?

The Il3ra can regulate the proliferation and differentiation of different types of immune cells in the immune system, thus affecting the function of the immune system.

Does Il3ra have side effects?

Il3ra is generally well tolerated, but some minor side effects such as headache and nausea may occur. Serious side effects are rare.